Sleep, 24-h activity rhythms, and plasma markers of neurodegenerative disease by Lysen, T.S. (Thom) et al.
1
Vol.:(0123456789)
Scientific Reports |        (2020) 10:20691  | https://doi.org/10.1038/s41598-020-77830-4
www.nature.com/scientificreports
Sleep, 24‑h activity rhythms, 
and plasma markers 
of neurodegenerative disease
Thom S. Lysen, M. Arfan Ikram, Mohsen Ghanbari & Annemarie I. Luik*
Sleep and 24‑h activity rhythm disturbances are associated with development of neurodegenerative 
diseases and related pathophysiological processes in the brain. We determined the cross‑sectional 
relation of sleep and 24‑h activity rhythm disturbances with plasma‑based biomarkers that might 
signal neurodegenerative disease, in 4712 middle‑aged and elderly non‑demented persons. Sleep 
and activity rhythms were measured using the Pittsburgh Sleep Quality Index and actigraphy. Simoa 
assays were used to measure plasma levels of neurofilament light chain, and additionally β‑amyloid 
40, β‑amyloid 42, and total‑tau. We used linear regression, adjusting for relevant confounders, and 
corrected for multiple testing. We found no associations of self‑rated sleep, actigraphy‑estimated 
sleep and 24‑h activity rhythms with neurofilament light chain after confounder adjustment and 
correction for multiple testing, except for a non‑linear association of self‑rated time in bed with 
neurofilament light chain (P = 2.5*10−4). Similarly, we observed no significant associations with 
β‑amyloid 40, β‑amyloid 42, and total‑tau after multiple testing correction. We conclude that sleep 
and 24‑h activity rhythm disturbances were not consistently associated with neuronal damage as 
indicated by plasma neurofilament light chain in this population‑based sample middle‑aged and 
elderly non‑demented persons. Further studies are needed to determine the associations of sleep and 
24‑h activity rhythm disturbances with NfL‑related neuronal damage.
Sleep and 24-h activity rhythm disturbances have been implicated in the etiology of clinical neurodegenerative 
diseases and several pathophysiological processes in the  brain1–4. The habitual level of disturbed sleep and 24-h 
activity rhythms, as a repetitive exposure of potential insults to the brain over a prolonged period of  time1,3, may 
be particularly important for pathophysiological processes in the brain. Although most studies on the effect of 
sleep and 24-h activity rhythm disturbances have focused on β-amyloid and tau pathology, central hallmarks of 
Alzheimer’s  disease1,3,5, plasma markers of neuronal damage have been studied  less5.
Neuronal damage can be captured in vivo by cerebrospinal fluid levels of the cytoskeletal protein neurofila-
ment light chain (NfL)6,7. Importantly, NfL can also be determined less invasively in  blood8, higher levels of 
which may mark neurodegenerative diseases and other neurological  disorders9–11. Moreover, NfL in blood has 
been shown to consistently rise at a higher rate years before the diagnosis in persons who eventually develop 
Alzheimer’s disease versus healthy  controls10,12. This suggests NfL can be used as a biomarker of clinically relevant 
pathophysiological processes in the brain, even though NfL in blood may lag behind neuronal damage, e.g. one 
month after an isolated neurosurgical  trauma13. Additionally, at a cellular level, NfL release may signal neuro-
axonal damage that does not necessarily lead to neuronal  loss14,15. This suggest that NfL may be of added value to 
existing studies using non-invasive neuroimaging markers as it may detect more subtle damage to the  brain5,16,17.
Several studies used NfL to determine the relation of sleep, but not yet 24-h activity rhythms, with neuronal 
 damage18–25. One study showed that persons with chronic insomnia disorder have higher serum NfL than con-
trols, which may decrease after  treatment18. Others found no relation of disordered, subjectively impaired or 
experimentally deprived sleep with NfL in CSF or  plasma19–25. No large-scale population-based study has yet 
investigated associations of objectively estimated habitual sleep and 24-h activity rhythm disturbances with 
neuronal damage indicated by NfL, even though this repetitive exposure of disturbed sleep might impact neu-
ronal damage.
We therefore tested the association of habitual sleep and 24-h activity rhythms with neuronal damage in 
middle-aged and elderly non-demented individuals from the population-based Rotterdam Study cohort. We 
assessed characteristics of habitual sleep and 24-h activity rhythms with a self-reported questionnaire indicating 
sleep quality over the past month and one week of actigraphy, which estimates sleep and 24-h activity rhythms 
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objectively based on wrist movement. These modalities have been suggested to tap into different aspects of 
habitual  sleep26. We assessed NfL in plasma to indicate neuronal damage. We hypothesized that self-rated and 
actigraphy-estimated poor sleep, and disturbed 24-h activity rhythms were associated with higher plasma NfL. 
For comparison, we also studied associations of sleep and 24-h activity rhythms with other plasma biomarkers 
of pathophysiological processes in the brain (β-amyloid 40 [Aβ40], Aβ42, and total tau [t-tau]).
Methods
Study setting. This study is embedded in the population-based, prospective Rotterdam Study cohort, which 
includes individuals from a suburban district in Rotterdam, the  Netherlands27. The cohort was initiated in 1990, 
including 7983 participants aged ≥ 55 years, and was expanded in 2000 with 3011 participants aged ≥ 55 years, 
and again in 2006 with persons aged ≥ 45 years, totaling 14,926 participants. Examination rounds include a home 
interview and subsequent visits to our dedicated research center, and are repeated every 4 to 5 years.
The Rotterdam Study has been approved by the medical ethics committee of the Erasmus MC (registration 
number MEC 02.1015) according to the Population Screening Act, executed by the Ministry of Health, Welfare 
and Sports of the Netherlands. The study was performed in accordance with the Declaration of Helsinki. Written 
informed consent was obtained from all participants.
Study population. Between 2002 and 2005, 6044 participants from the initiation and first expansion 
cohort underwent venipuncture at the research center. Of those, 5069 had sufficient plasma stores available for 
analyzing biomarkers. We excluded 232 persons without valid data on plasma NfL, and 20 persons with all-cause 
dementia to focus on at-risk individuals only. From the remaining 4817 participants, 4712 provided valid data 
on ≥ 1 questionnaire-derived sleep parameter (4353 persons provided data on all parameters).
Also, out of aforementioned 4817 participants, 1346 individuals were invited to participate in an actigraphy 
 study28; 970 agreed. Of these, 849 persons (88%) provided valid data for a minimum of 4 consecutive 24-h 
 periods28.
Self‑rated sleep. Participants rated their sleep using a Dutch version of the Pittsburgh Sleep Quality Index 
 (PSQI29). The PSQI measures sleep over the past month, and has good test–retest reliability and validity in a non-
clinical sample of older adults. Items include bedtimes and total sleep time at night, from which we derived time 
in bed and sleep efficiency, and time to fall asleep (sleep latency). Additionally, all items were summed to obtain 
the global PSQI score, indicating subjective sleep quality. The PSQI score ranges from 0–21, and higher scores 
indicate a poorer subjective sleep quality.
We excluded persons missing ≥ 2 PSQI components (n = 60), and calculated a weighted global PSQI score 
when only 1 component was missing (n = 173) by multiplying the six-component sum score by 7/6. The PSQI 
was completed a median of 18 days (interquartile range [IQR] = 17–19) before venipuncture.
Objectively estimated sleep and 24‑h activity rhythms. Participants wore an actigraph (Actiwatch 
model AW4, Cambridge Technology Ltd.) which measures acceleration summed as ‘activity counts’ per 30-s 
epochs. We instructed participants to wear the actigraph for 7 days and nights around the non-dominant wrist, 
and to remove it only while bathing. Participants had to press a marker button on the device when attempting 
to fall asleep (hereafter: ‘lights out’), and when getting out of bed the next morning (hereafter: ‘lights on’). They 
also kept a daily sleep  diary28. Missing marker times (25%) were imputed from the diary, or estimated by inspect-
ing recordings if diary times were missing. We removed 24-h periods containing > 3 continuous hours without 
activity to prevent bias from removal of data around specific times of the day. Actigraphy recordings averaged 
137.9 ± 13.6  h, and were initiated a median of 28  days (IQR 9–287) after venipuncture. Within the marker-
defined time in bed, we estimated sleep (i.e. total sleep time) and wakefulness using a validated algorithm with 
a threshold of 20  counts28. We defined ‘sleep start’ as the midpoint of the first immobile ≥ 10 min period after 
‘lights out’ with ≤ 1 epoch containing  activity28. Sleep onset latency was calculated as the time from ‘lights out’ 
to ‘sleep start’, and wake after sleep onset as wakefulness after ‘sleep start’. We calculated sleep efficiency as total 
sleep time divided by time in bed * 100%.
We also used counts to calculate non-parametric indices of the 24-h activity rhythm: Intradaily variability 
which indicates the amount of alterations of activity-inactivity, interdaily stability which indicates how daily 
profiles in the recording resemble each other, and onset time of the least active 5 consecutive hours (L5 onset) 
which indicates the phase of lowest activity. A disturbed 24-h activity rhythm is reflected by high intradaily 
variability and interdaily stability.
Measurement of plasma concentrations of NfL, Aβ40, Aβ42, and t‑tau. Participants came to the 
dedicated research center where a venipuncture was performed between 8:00 and 10:30 in the morning after an 
overnight fast. Blood was sampled in ethylenediamine tetra-acetic acid-treated containers and centrifuged. The 
plasma was aliquoted and frozen at − 80 °C according to standard procedures. In 2018, samples were assessed 
through the Janssen Prevention Center (Leiden, NL) which sent plasma to the laboratory facilities of Quanterix 
(Lexington, MA, USA). Analyses were performed on a single molecule array (Simoa) HD-1 analyzer platform 
in two  batches30. Concentrations of biomarkers were measured using the NF-light advantage  kit31 (for NfL), and 
the Simoa Human Neurology 3-Plex A assay (for Aβ40, Aβ42, and t-tau). Samples were tested in duplicate, two 
quality control samples were run on each plate per biomarker. Technical data on assay performance was pub-
lished  previously10. Data was excluded if duplicates or single measurements were missing, if the concentration 
coefficient of variation exceeded 20%, or if control samples were out of range.
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Covariates. As potential confounders we selected possible causes of the determinant or the outcome, or 
proxies of such  factors32–34, in line with recent  literature35. We considered age, sex, education (categorized as pri-
mary, secondary/lower vocational, intermediate vocational and higher vocational/university), batch number of 
biomarker analysis, time interval between measurements of sleep and biomarker, habitual alcohol consumption, 
presence of self-reported paid employment, smoking status (never, former, current), body mass index (BMI), 
presence of hypertension (resting blood pressure > 140/90 mmHg, or use of blood pressure-lowering medica-
tion), presence of diabetes mellitus (fasting serum glucose level ≥ 7.0 mmol/l, or use of glucose-lowering medica-
tion), total cholesterol level in serum in mmol/l, a positive history of heart disease (myocardial infarction, heart 
failure, or coronary revascularization procedure), and possible sleep apnea defined using PSQI items on loud 
snoring and respiratory pauses. Measurements were performed during the home interview or center visits, as 
detailed  previously36.
Additionally, we assessed clinically relevant depressive symptoms defined as a score < 16 on the validated 
Dutch version of the Centre for Epidemiological Studies-Depression scale (CES-D), cognitive impairment defined 
by a Mini Mental State Examination (MMSE) score ≤ 25, and a history of stroke ascertained during examination 
rounds and by continuous monitoring as detailed previously.
Statistical analysis. All sleep parameters were winsorized at 3 SD from the mean, and subsequently stand-
ardized. Biomarker values were log-transformed (base = 2) to approach a normal distribution, winsorized to 3 
SD and standardized to facilitate comparison across different biomarkers.
We used linear regression to analyze the association of sleep and 24-h activity rhythm parameters with 
plasma NfL. We investigated self-rated sleep (PSQI score, total sleep time, sleep onset latency, time in bed, and 
sleep efficiency), actigraphy-estimated sleep (total sleep time, sleep onset latency, wake after sleep onset, time in 
bed, sleep efficiency), 24-h activity rhythms (intradaily variability, interdaily stability and L5 onset) and times of 
‘lights out’ and ‘lights on’. Analyses were adjusted for age, sex, educational level, batch, and time interval between 
measurements of sleep and biomarkers (model 1), and additionally for alcohol consumption, paid employment 
status, smoking status, BMI, hypertension, diabetes mellitus, total cholesterol, history of heart disease, and 
possible sleep apnea (model 2). Furthermore, as total sleep time and time in bed are known to show U-shaped 
relations with various poor health outcomes, we assessed non-linear associations of these parameters (self-rated 
and actigraphy-estimated) with NfL by adding their quadratic terms to the model.
We additionally restricted analyses to persons without clinically relevant depressive symptoms, without cog-
nitive impairment, and without prevalent stroke. Depressive symptoms may strongly influence sleep and sleep’s 
 appraisal37, and depression is associated with cortical  abnormalities38. Cognitive impairment is a proxy for the 
accumulation of detrimental processes in the brain potentially influencing the relation of sleep or 24-h activity 
rhythms with neurodegeneration, and may influence reporting of sleep. Likewise, prevalent stroke is a proxy for 
higher loads of cerebrovascular disease potentially affecting NfL and  sleep33,34.
Besides NfL, other biomarkers may also be potentially important. Therefore, we also examined associations of 
sleep and 24-h activity rhythms with other plasma biomarkers of neurodegenerative disease: Aβ40, Aβ42, and t-tau.
We performed statistical testing with two-tailed tests, and considered associations below the threshold of 
P < 0.0046 as statistically significant, which corrected for testing 15 self-rated and actigraphy-estimated param-
eters in this study. This threshold was defined by computing the number of effective tests  (Meff = 11.14) based on 
correlations between all parameters, and applying a Sidak correction. We considered associations as nominally 
significant at P < 0.05.
Missing values on covariates were imputed using five multiple imputations with IBM SPSS Statistics version 
24 (IBM Corp, Armonk, NY). Analyses were performed with R  software39.
Results
We included 4712 participants (mean age 72 ± 8 years, 57% female), see Table 1. The median plasma NfL level 
was 13.3 pg/mL (IQR 10.0–18.4).
Sleep parameters. For self-rated sleep parameters, we found no significant linear associations with plasma 
NfL in model 2 (Table 2). The association of self-rated longer time in bed with higher NfL in model 1 (beta per 
standard deviation [SD] increase in self-rated time in bed of 0.038 SD increase in  log2(NfL), 95% confidence 
interval [CI] 0.015; 0.060, P = 0.0013) attenuated after additional adjustment (Table 2). The quadratic term of 
self-rated time in bed was significantly associated with NfL in model 2 (P = 2.5*10−4). Compared to a self-rated 
normal time in bed (7–9 h), spending a long time in bed (> 9 h) was significantly associated with higher NfL 
(0.171, 95% CI 0.086; 0.256, P = 7.7*10−5), but spending a short time in bed (< 7 h) was not (− 0.008, 95% CI 
− 0.057; 0.041, P = 0.75).
Actigraphy-estimated sleep parameters were not related to NfL in plasma (Table 2). We found no non-linear 
associations for actigraphy-estimated total sleep time and time in bed.
24‑h activity rhythm parameters. We observed no significant associations of 24-h activity rhythm 
parameters with NfL beyond the multiple testing corrected threshold (Table 3).
Sensitivity analysis. Restricting the main analysis to individuals without clinically relevant depressive 
symptoms, without cognitive impairment or stroke overall did not substantially change effect sizes (Table 4). For 
self-rated time in bed, estimates were attenuated after excluding persons with cognitive impairment, and to a 
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Associations with plasma Aβ‑isoforms and total tau. For comparison, we also investigated associa-
tions of sleep and 24-h activity rhythm parameters with other biomarkers of neurodegenerative disease. Median 
(IQR) plasma levels in pg/mL for 4712 persons were 259.5 (230.3–294.0) for Aβ40, 10.3 (8.8–11.9) for Aβ42, and 
2.4 (1.9–3.0) for t-tau. In comparison to associations with NfL, we observed more associations exceeding P < 0.05 
including associations of poorer subjective sleep quality, longer self-rated time in bed and lower self-rated sleep 
efficiency with higher plasma concentrations of β-amyloid isoforms (Table 5). Yet, no association was statisti-
cally significant beyond the threshold corrected for multiple testing (Table 5).
Table 1.  Characteristics of study population. Characteristics of the study population. Values are expressed as 
frequency (%) for categorical variables and mean ± standard deviation or median (1st quartile–3rd quartile) 
for continuous variables. Includes imputed values for covariates. Missing values for self-rated sleep parameters 
were 60 for PSQI score, 58 for sleep duration, 198 for sleep latency, 159 for time in bed, and 212 for sleep 
efficiency. a Actigraphic time in bed was not automatically calculated but based on ‘lights out’ and ’lights on’ 
times specified daily by participants using the actigraph marker buttons and a sleep diary. L5 least active 5 h of 
the day, N sample size, PSQI Pittsburgh Sleep Quality Index.
Characteristic (unit)
Total sample Actigraphy subsample
N = 4712 N = 849
Age at sleep measurement (years) 71.1 (66.1–77.2) 66.7 (63.7–73.1)
Female 2700 (57%) 433 (51%)
Educational level
Primary education 536 (11%) 53 (6%)
Lower/intermediate or lower vocational 2088 (44%) 368 (43%)
Higher or intermediate vocational 1436 (31%) 281 (33%)
Higher vocational or university 652 (14%) 147 (18%)
Alcohol consumption (g/day) 7 (1–20) 9 (1–20)
Paid employment 303 (6%) 74 (9%)
Smoking status
Never 1480 (31%) 264 (31%)
Former 2598 (55%) 477 (56%)
Current 634 (13%) 108 (13%)
Body mass index (kg/m2) 27.6 ± 4.1 27.9 ± 4.0
Hypertension 2569 (54%) 414 (49%)
Diabetes mellitus 472 (10%) 84 (10%)
Total cholesterol in serum (mmol/l) 5.6 ± 1.0 5.7 ± 1.0
History of heart disease 704 (15%) 89 (10%)
Possible sleep apnea 580 (12%) 113 (13%)
Self-rated sleep
Global PSQI score 3 (2–6) 3 (1–6)
Duration (h) 6.8 ± 1.3 6.9 ± 1.2
Latency (min) 10 (5–30) 10 (5–30)
Time in bed (h) 7.7 ± 1.1 7.7 ± 1.0
Efficiency (%) 93 (83–99) 93 (86–100)
Actigraphic sleep and 24 h activity rhythms
Total sleep time (h) – 6.5 ± 0.8
Latency (min) – 18 (12–26)
Wake after sleep onset (h) – 1.1 (0.9–1.4)
Time in bed (h)a – 8.3 ± 0.8
Efficiency (%) – 79 (74–83)
Intradaily variability (score) – 0.41 (0.34–0.52)
Interdaily stability (score) – 0.83 (0.76–0.88)
L5 onset (hh:mm) – 01:53 ± 01:10
‘Lights out’ time (hh:mm)a – 23:51 ± 00:48
‘Lights on’ time (hh:mm)a – 08:10 ± 00:45
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Discussion
In this population-based study in middle-aged and elderly persons, sleep and 24-h activity rhythms were not 
associated with plasma NfL, except for a non-linear association of self-rated time in bed with NfL.
We only found a non-linear association of self-rated time in bed with NfL. This is in line with findings that 
more sedentary behavior, although distinct from sleep, is linked to various poor health outcomes which may 
impact neuronal  damage40. We might speculate that the association of self-rated long time in bed with higher 
plasma NfL could be due to a shared common cause such as overall poor health or underlying subclinical 
 disease41,42. Indeed, the linear association of self-rated time in bed with NfL is attenuated after additional adjust-
ment in model 2 and when persons with cognitive impairment or stroke, but not depressive symptoms, were 
excluded. This suggests that poor physical health or clinical diseases could underlie the association of time in 
bed with NfL. Other potential factors underlying the link of longer time in bed with poor health outcomes may 
be fatigue, immune function, or sleep  apnea42. Further research may consider investigating if self-rated time in 
bed indeed validly marks poor health, and how it relates to other sleep-related  markers41. Of note, this association 
Table 2.  Associations of self-rated and actigraphy-estimated sleep parameters with neurofilament light chain 
levels in plasma. Estimates represent that, with a standard deviation increase in the independent variable, 
the level of neurofilament light chain (NfL) increases by beta*standard deviation (SD)  log2 pg/mL. Estimates 
were obtained with linear regression, adjusted for age and sex, educational level, batch, time interval between 
measurement of sleep and biomarkers (model 1), and additionally for alcohol consumption, employment 
status, smoking status, body mass index, presence of hypertension, presence of diabetes mellitus, total 
serum cholesterol level, history of cardiovascular disease, and possible sleep apnea (model 2). Analyses were 
performed in n = 4652 persons for PSQI score, in n = 4654 for sleep duration, in n = 4514 for sleep latency, 
in n = 4552 for time in bed, and in n = 4499 for sleep efficiency. Actigraphy analyses were performed in 849 
persons. a Please note that actigraphy-derived time in bed was not automatically calculated but based on ‘lights 
out’ and ‘lights on’ times, specified daily by participants using actigraph marker buttons and a sleep diary. CI 
confidence interval, PSQI Pittsburgh Sleep Quality Index.
Independent variables
Model 1 Model 2
Beta (95% CI) P Beta (95% CI) P
Self-rated
PSQI score 0.023 (− 0.001; 0.046) 0.06 0.014 (− 0.009; 0.036) 0.23
Sleep duration 0.005 (− 0.018; 0.027) 0.68 0.007 (− 0.015; 0.028) 0.56
Sleep latency 0.017 (− 0.010; 0.044) 0.23 0.006 (− 0.020; 0.032) 0.65
Time in bed 0.038 (0.015; 0.060) 0.001 0.032 (0.009; 0.054) 0.01
Sleep efficiency − 0.032 (− 0.056; − 0.008) 0.01 − 0.025 (− 0.048; − 0.001) 0.04
Actigraphy-estimated
Total sleep time − 0.006 (− 0.058; 0.047) 0.83 − 0.030 (− 0.082; 0.022) 0.26
Sleep latency − 0.008 (− 0.062; 0.045) 0.76 − 0.004 (− 0.057; 0.048) 0.88
Wake after sleep onset 0.023 (− 0.028; 0.073) 0.37 0.021 (− 0.028; 0.071) 0.40
Time in  beda 0.001 (− 0.051; 0.053) 0.97 − 0.021 (− 0.073; 0.030) 0.41
Sleep efficiency − 0.004 (− 0.055; 0.047) 0.87 − 0.016 (− 0.066; 0.034) 0.52
Table 3.  Associations of actigraphy-estimated 24-h activity rhythm parameters and bedtimes with 
neurofilament light chain in plasma. Estimates represent that, with a standard deviation increase in the 
independent variable, the level of neurofilament light chain (NfL) increases by beta*standard deviation 
(SD)  log2 pg/mL. Estimates were obtained with linear regression, adjusted for age and sex, educational level, 
batch, time interval between measurement of sleep and biomarkers (model 1), and additionally for alcohol 
consumption, employment status, smoking status, body mass index, presence of hypertension, presence of 
diabetes mellitus, total serum cholesterol level, history of cardiovascular disease, and possible sleep apnea 
(model 2). Analyses were all performed in 849 persons. a Please note that actigraphy-derived bedtimes were 
specified daily by participants using actigraph marker buttons and a sleep diary. CI confidence interval, L5 
average least active 5 h of the day, SD standard deviation.
Independent variables
Model 1 Model 2
Beta (95% CI) P Beta (95% CI) P
Intradaily variability 0.022 (− 0.033; 0.078) 0.43 0.036 (− 0.019; 0.092) 0.19
Interdaily stability 0.000 (− 0.051; 0.052) 0.99 − 0.017 (− 0.068; 0.033) 0.50
L5 onset − 0.008 (− 0.059; 0.043) 0.76 − 0.005 (− 0.054; 0.045) 0.85
‘Lights out’  timea − 0.050 (− 0.103; 0.004) 0.07 − 0.033 (− 0.086; 0.020) 0.22
‘Lights on’  timea − 0.044 (− 0.095; 0.008) 0.10 − 0.049 (− 0.100; 0.001) 0.06
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was only present when time in bed was assessed through general retrospective ratings of bedtimes over the last 
month, but not when time in bed was based on averages obtained from prospectively collected marker buttons 
or daily sleep diaries. This might be explained by a difference in operationalization: the PSQI assesses time in 
bed independent of whether a person tries to sleep when in bed whereas this is taken into account in the assess-
ments with actigraphy and sleep diary. Additionally, as retrospective questionnaire ratings tend to suffer more 
from recall bias than prospective measurements, it might also be that the association is driven by factors related 
to recall bias rather than time in bed per se, such as cognitive impairment.
Recently, we demonstrated that actigraphy-estimated poor sleep was associated with the risk of clinical all-
cause dementia and Alzheimer’s disease in the Rotterdam Study. Yet, sleep and 24-h activity rhythm disturbances 
are not clearly associated with NfL in the current study which is embedded in the same cohort, suggesting that 
poor sleep does not affect neuronal damage as indicated by NfL. Our finding partly contradicts findings from 
other studies implementing non-invasive structural neuroimaging which do suggest that poor sleep and 24-h 
activity rhythms are related to global or regional loss of tissue or  integrity5,16,17. Together, these and our find-
ings suggest a role for non-neuronal, i.e. glial cells in the relation between sleep and pathology of the brain. A 
methodological explanation may be reverse causation; brain changes picked up by imaging affect sleep, while 
higher levels of plasma NfL may not necessarily indicate enough damage to the brain to affect sleep or activity 
rhythms. Of note, our findings are in line with previous studies that show that neuroimaging markers and NfL 
are correlated in the presence of neurodegenerative  disease9,43, but show little to no correlations in otherwise 
healthy  individuals43–45. Possibly, NfL may reflect brain pathology on imaging only once a certain threshold is 
exceeded, a suggestion also highlighted by a recent  study46.
The lack of an association of sleep and 24-h activity rhythms with NfL could be explained in several ways. 
First, habitually disturbed sleep and 24-h activity rhythms may affect neuronal health yet do not lead to NfL 
release. At a cellular level, release of NfL, most abundantly present in the axon, occurs after apoptosis or axon-
specific neuronal  insults14,15. Sleep or 24-h activity rhythm disturbances may involve neuronal insults that, 
Table 4.  Associations of sleep with neurofilament light chain in plasma in persons without depressive 
symptoms, cognitive impairment or stroke. Absence of depressive symptoms was defined as CES-D score ≥ 16; 
absence of cognitive impairment was defined as MMSE score > 25. Estimates represent that, with a standard 
deviation increase in the independent variable, the level of neurofilament light chain (NfL) increases by 
beta*standard deviation (SD)  log2 pg/mL. Estimates were obtained with linear regression, adjusted for age 
and sex, educational level, batch, time interval between measurement of sleep and biomarkers, alcohol 
consumption, employment status, smoking status, body mass index, presence of hypertension, presence of 
diabetes mellitus, total serum cholesterol level, history of cardiovascular disease, and possible sleep apnea. For 
self-rated independent variables, cases per analysis ranged from 4048 to 4181 restricted to persons without 
depressive symptoms, from 3908 to 4042 in persons without cognitive impairment, and from 4288 to 4431 
in persons without prevalent stroke. For actigraphy-derived independent variables, cases in analyses were 
n = 785 (depressive symptoms), n = 756 (cognitive impairment) and n = 817 (stroke). *Nominal significance at 
P < 0.05. † P = 0.0034. a Actigraphic time in bed was not automatically calculated but determined by ‘lights out’ 
and ’lights on’ times specified through pressing actigraph marker buttons and the sleep diary. CES-D Center 
for Epidemiological Studies-Depression scale, CI confidence interval, IS interdaily stability, IV intradaily 
variability, L5 average least active 5 h of the day, MMSE mini-mental state examination, PSQI Pittsburgh Sleep 
Quality Index, SD standard deviation, SE sleep efficiency, SOL sleep onset latency, TIB time in bed, TST total 
sleep time, WASO wake after sleep onset.
Independent variables
No depressive symptoms No cognitive impairment No stroke
Beta (95% CI) Beta (95% CI) Beta (95% CI)
Self-rated
PSQI − 0.001 (− 0.026; 0.024) 0.007 (− 0.017; 0.032) 0.010 (− 0.013; 0.033)
TST 0.015 (− 0.009; 0.039) 0.001 (− 0.023; 0.025) 0.006 (− 0.016; 0.028)
SOL 0.001 (− 0.029; 0.030) − 0.001 (− 0.029; 0.028) 0.001 (− 0.026; 0.028)
TIB 0.036 (0.012; 0.059)† 0.022 (− 0.002; 0.046) 0.028 (0.006; 0.051)*
SE − 0.017 (− 0.042; 0.009) − 0.022 (− 0.047; 0.003) − 0.022 (− 0.046; 0.001)
Actigraphy
TST − 0.024 (− 0.077; 0.030) − 0.027 (− 0.085; 0.030) − 0.029 (− 0.082; 0.025)
SOL − 0.013 (− 0.069; 0.042) − 0.003 (− 0.061; 0.054) − 0.003 (− 0.055; 0.049)
WASO 0.011 (− 0.040; 0.062) 0.016 (− 0.037; 0.069) 0.021 (− 0.029; 0.070)
TIB‡ − 0.032 (− 0.086; 0.021) − 0.029 (− 0.085; 0.028) − 0.016 (− 0.069; 0.036)
SE − 0.001 (− 0.053; 0.051) − 0.010 (− 0.064; 0.044) − 0.016 (− 0.066; 0.034)
IV 0.018 (− 0.039; 0.076) 0.046 (− 0.015; 0.107) 0.042 (− 0.012; 0.097)
IS − 0.006 (− 0.058; 0.047) − 0.018 (− 0.074; 0.038) − 0.010 (− 0.060; 0.041)
L5 onset − 0.014 (− 0.065; 0.037) − 0.023 (− 0.076; 0.031) 0.003 (− 0.047; 0.053)
Lights  out‡ − 0.035 (− 0.089; 0.020) − 0.029 (− 0.086; 0.027) − 0.039 (− 0.091; 0.014)
Lights  ona − 0.063 (− 0.115; − 0.010)* − 0.055 (− 0.111; 0.001) − 0.050 (− 0.101; 0.001)
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through invoking various stress responses, impair neuronal function but do not lead to apoptosis. Second, we 
measured sleep with questionnaires and actigraphy. These measurements may not have captured relevant sleep 
disorders such as insomnia or sleep-disordered breathing, or physiological aspects of sleep such as slow-wave 
activity. This could explain why a previous study showed higher serum NfL in persons with chronic insomnia 
versus  controls18, while we found no association of subjective sleep quality, an insomnia-related construct, with 
NfL in the general population. Third, neuronal insults related to sleep and 24-h activity rhythm disturbances 
may not be severe enough to elevate NfL in plasma. Our hypothesis on the detrimental effects of poor sleep for 
neuronal health was based on mechanistic, animal-based studies that mostly used experimental sleep deprivation. 
However, we studied observational differences in habitual sleep, and these more chronic disturbances might be 
associated with less harm to neuronal health than experimentally induced reductions in sleep. Indeed, a previous 
study also did not find an association of observational differences in subjective sleep quality with NfL, using CSF 
 measurements20. Additionally, experimentally depriving individuals of sleep to 4 h for five nights did not affect 
NfL in  CSF19 or  blood22. One night of total sleep deprivation also did not change NfL in  blood24.
Compared to NfL, associations of sleep and 24-h activity rhythms with Aβ40, Aβ42 and t-tau in plasma were 
largely similar. Estimates suggested nominally significant relations for self-rated time in bed, and the related 
variable of sleep efficiency, comparable to findings for NfL. Yet, no associations survived multiple testing correc-
tion. These null findings for β-amyloid were in contrast to our expectations as sleep has been shown to regulate 
brain β-amyloid  levels47, and habitual sleep has been associated with CSF β-amyloid, and parenchymal β-amyloid 
 deposition5. Also, lower plasma Aβ42 was associated with a higher risk of Alzheimer’s disease in our  cohort10. 
We measured Aβ42 in plasma which may differ or be less precise than measurements in  CSF48, thus potentially 
obscuring detection of an association.
For tau, we could also not confirm findings of previous studies linking disturbed or disordered sleep to tau 
brain  pathology23,49,50 or total tau in  blood51, which may in part be explained by the use of polysomnography-
derived characteristics of sleep in these studies.
Several methodological considerations need to be mentioned. First, our largely negative findings could indi-
cate that our biomarker measurements, using plasma instead of CSF, were invalid. Yet, high NfL and reduced Aβ42 
in plasma have been associated with risk of clinical all-cause dementia and Alzheimer’s disease in non-demented 
Table 5.  Associations of sleep and 24-h activity rhythms with biomarkers of neurodegenerative disease in 
plasma. Estimates represent that, with a standard deviation increase in the independent variable, the level 
of neurofilament light chain (NfL) increases by beta*standard deviation (SD)  log2 pg/mL. Estimates were 
obtained with linear regression, adjusted for age and sex, educational level, batch, time interval between 
measurement of sleep and biomarkers, alcohol consumption, employment status, smoking status, body 
mass index, presence of hypertension, presence of diabetes mellitus, total serum cholesterol level, history of 
cardiovascular disease, and possible sleep apnea. Numbers of cases per analysis differed as both independent 
variables and outcomes had different numbers of missing values. For self-rated independent variables, 
numbers varied from 4486 (association total sleep time with total tau) to 4145 (sleep efficiency with β-amyloid 
42). For actigraphy-derived independent variables (all n = 849), numbers varied from 824 (total tau) to 806 
(β-amyloid 42). *Nominal significance at P < 0.05. a Actigraphic time in bed was not automatically calculated 
but based on ‘lights out’ and ’lights on’ times specified by participants. CI confidence interval, IS interdaily 
stability, IV intradaily variability, L5 average least active 5 h of the day, PSQI Pittsburgh Sleep Quality Index, SD 
standard deviation, SE sleep efficiency, SOL sleep onset latency, TIB time in bed, TST total sleep time, WASO 
wake after sleep onset.
Independent variables
β-amyloid 40 β-amyloid 42 Total tau
Beta (95% CI) Beta (95% CI) Beta (95% CI)
Self-rated
PSQI score 0.020 (− 0.008; 0.047) 0.030 (0.002; 0.057)* − 0.016 (− 0.045; 0.013)
TST 0.005 (− 0.021; 0.032) − 0.007 (− 0.034; 0.020) 0.018 (− 0.009; 0.046)
SOL 0.008 (− 0.025; 0.040) 0.009 (− 0.023; 0.041) − 0.002 (− 0.036; 0.031)
TIB 0.033 (0.006; 0.060)* 0.032 (0.005; 0.059)* 0.019 (− 0.009; 0.047)
SE − 0.020 (− 0.048; 0.008) − 0.038 (− 0.066; − 0.010)* 0.008 (− 0.021; 0.038)
Actigraphy
TST − 0.051 (− 0.116; 0.013) − 0.025 (− 0.086; 0.036) 0.034 (− 0.032; 0.100)
SOL − 0.001 (− 0.066; 0.064) 0.019 (− 0.042; 0.080) 0.007 (− 0.060; 0.074)
WASO 0.049 (− 0.012; 0.110) 0.051 (− 0.006; 0.109) 0.045 (− 0.018; 0.108)
TIBa − 0.036 (− 0.099; 0.028) 0.005 (− 0.055; 0.065) 0.061 (− 0.004; 0.127)
SE − 0.047 (− 0.109; 0.015) − 0.050 (− 0.108; 0.008) − 0.028 (− 0.092; 0.036)
IV 0.066 (− 0.002; 0.134) − 0.002 (− 0.067; 0.062) − 0.007 (− 0.077; 0.063)
IS − 0.022 (− 0.085; 0.041) 0.018 (− 0.041; 0.077) − 0.025 (− 0.089; 0.040)
L5 onset 0.019 (− 0.042; 0.080) 0.027 (− 0.031; 0.085) 0.020 (− 0.043; 0.083)
Lights  outa 0.007 (− 0.058; 0.072) − 0.017 (− 0.079; 0.044) 0.019 (− 0.048; 0.085)
Lights  ona − 0.027 (− 0.089; 0.036) − 0.017 (− 0.076; 0.042) 0.074 (0.010; 0.139)*
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individuals in our  cohort10, suggesting they may reflect neurodegenerative disease in a preclinical phase. Second, 
correlations of NfL between CSF and plasma are lower in healthy versus diseased persons, lowering our sensitivity 
to detect relevant plasma NfL increases, especially in the actigraphy subgroup. Third, associations with plasma 
NfL may not reflect increased damage but differential equilibration across fluid compartments, as poor sleep 
may disturb blood–brain barrier function. Fourth, cross-sectional associations may not have been detected as 
plasma NfL levels may lag behind neuronal injury, e.g. on average one month after an isolated neurosurgical 
 trauma13. Yet, our single sleep measures are relatively stable over time, as are plasma NfL levels across years in 
relation to neurodegenerative  diseases10,43, and we adjusted analyses for the time interval between measurements. 
Additionally, our cross-sectional design prevents us from speculating on the temporality of any associations. 
Fifth, actigraphy estimates may misclassify sleep and only indirectly reflect circadian functioning. Sixth, we could 
not investigate the influence of physical activity on our estimates, as the Actiwatch model used in this study was 
not suited for quantifying physical activity. Study strengths include using a large sample anchored in the general 
population, measuring sleep with two modalities, simultaneously investigating multiple relevant biomarkers, 
and correcting for various confounders.
In conclusion, our findings do not indicate a consistent relation of sleep and 24-h activity rhythm distur-
bances with plasma NfL in our population-based sample of middle-aged and elderly non-demented persons. 
Additionally, sleep and 24-h activity rhythm disturbances seemed also unrelated to Aβ40, Aβ42 and t-tau in plasma. 
Further studies across different populations are needed to determine whether sleep and 24-h activity rhythms 
disturbances are not associated with neuronal damage assessed with plasma NfL.
Data availability
Data can be obtained on request. Requests should be directed toward the management team of the Rotterdam 
Study (secretariat.epi@erasmusmc.nl), which has a protocol for approving data requests. Because of restrictions 
based on privacy regulations and informed consent of the participants, data cannot be made freely available in 
a public repository.
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